Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00597246 · ClinicalTrials.gov registry record · NA
Imaging Brain Tumors With FACBC and Methionine
A NA study of Brain Cancer and CNS Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00597246: Completed NA study of Brain Cancer and CNS Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00597246 is a NA study of Brain Cancer and CNS Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 30 participants, below the 507-participant average among 47 other Brain Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00597246, a NA study of Brain Cancer and CNS Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This research protocol makes pictures of brain tumors. The pictures are made with a positron emission tomography (PET) scanner. PET scans use radioactivity to "see" cancer cells. We are using a new kind of PET scan. The new PET scan is called \[18F\]-FACBC PET. We will compare this to the standard PET scan. The standard PET scan is called \[11C\]-methionine PET. We expect these pictures will give us information about your tumor. We also hope to collect information about the amount of radioactivity exposure. We will measure radioactivity exposure to your tumor, brain and other organs. The research study results will be used to support the submission of an investigational new drug (IND) application to the Food and Drug Administration (FDA).
Primary Outcome
Determine clearance of 3-\[18F\]-FACBC in different tissues/organs of body.
Conditions Studied
Interventions
- OTHER PET Scan
- DRUG FACBC, Methionine
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-05-13 |
| Est. Completion | 2019-11-27 |
| Phase | NA |
What the finished NCT00597246 record still lists
NCT00597246 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 507-participant average among 47 other Brain Cancer trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Brain Cancer appearing as the primary indexed condition, and to 2 interventions - of which PET Scan is the first listed.
NCT00597246 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00597246 about?
NCT00597246 is a clinical study titled "Imaging Brain Tumors With FACBC and Methionine". This research protocol makes pictures of brain tumors. The pictures are made with a positron emission tomography (PET) scanner. PET scans use radioactivity to "see" cancer cells. We are using a new kind of PET scan. The new PET scan is called \[18F\]-FACBC PET. We will compare this to the standard P...
What is the current status of trial NCT00597246?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2003-05-13. Estimated completion is 2019-11-27.
What conditions does trial NCT00597246 study?
This clinical trial studies the following conditions: Brain Cancer, CNS Cancer.
What interventions are being tested in trial NCT00597246?
The interventions under investigation include: PET Scan (OTHER), FACBC, Methionine (DRUG).
Who is sponsoring clinical trial NCT00597246?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00597246 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00597246's enrollment target sits among peer trials
30 32nd of 47 higher than 14 of 47 other Brain Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors
RECRUITING · NA
-
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
RECRUITING · NA
-
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
RECRUITING · NA
-
HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)
RECRUITING · NA
-
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
RECRUITING · NA
-
Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI